Predictors of remission formation in the use of selective serotonin reuptake inhibitors in patients with non-psychotic depression comorbid with arterial hypertension
Suggested citation:
Kanaeva LS, Kvariantashvili EI, Vazagaeva TI. [Predictors of remission formation in the use of selective serotonin reuptake inhibitors in patients with non-psychotic depression comorbid with arterial hypertension]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2023;(1):23-32. Russian
In this open comparative non-randomized study of the effectiveness and clinical and social predictors of the formation of remission in the treatment of patients suffering from non-psychotic depression and hypertension, 83 patients were examined. In patients with non-psychotic comorbid depression with arterial hypertension (group 1, n=40), the percentage of achieving remission was significantly (p<0.05) lower (38.4%) than in patients with non-psychotic depression without arterial hypertension (group 2, n=43) (63.1%). Remission in the second group was formed at an earlier time (second week) compared to the first (third week) (p<0.05). Socio-demographic (employment in one’s own field of specialty), clinical (long duration of the disease at the time of treatment, asthenic type of depression) and therapeutic factors (early primary response, paroxetine therapy) contributed to the achievement of remission. Factors of arterial hypertension, absence of work due to retirement, apathetic type of depression were negative in prognostic terms. The prognosis of achieving remission decreased in the presence of arterial hypertension and increased in working patients and asthenic type of depression.
Keywords depression; antidepressants; selective serotonin reuptake inhibitors; arterial hypertension; efficacy; remission; efficacy predictors
1. Krasnov VN. [Depression and cardiovascular disease]. Praktikuyushchij vrach [Practicing doctor]. 2002;(2):31–2. (In Russ.) 2. Davies SJC, Jackson PR, Potokar J, Nutt DJ. Treatment of anxiety and depressive disorders in patients with cardiovascular disease. BMJ. 2004;328(7445):939–43. DOI: https://doi.org/10.1136/bmj.328.7445.939 3. CHazov EI, Oganov RG, Pogosova GV. [Program “Coordinate” (clinical and epidemiological program for the study of depression in cardiology practice in patients with arterial hypertension and coronary heart disease): results of the therapeutic part of a multicenter study]. Terapevticheskiĭ arhiv [Therapeutic archive]. 2006;(4):38–43. (In Russ.) 4. Celano CM, Huffman JC. Depression and Cardiac Disease. Cardiol Rev. 2011;19(3):130–42. DOI: https://doi.org/10.1097/CRD.0b013e31820e8106 5. Wassertheil-Smoller S, Applegate WB, Berge K, et al. Change in depression as a precursor of cardiovascular events. Arch Intern Med. 1996;156(5):553–61. PMID: 8604962 6. Oganov RG, Pogosova GV, Koltunov IE, et al. [Depressive symptoms worsen the prognosis of cardiovascular diseases and reduce the life expectancy of patients with arterial hypertension and coronary heart disease]. Kardiologiya [Cardiology]. 2011;(2);59–66. (In Russ.) 7. Smulevich AB, Syrkin AL, Drobizhev MYU, Ivanov SV. Psihokardiologiya. Moscow: MIA; 2005. 784 p. (In Russ.) 8. Duan S, Xiao J, Zhao S, Zhu X. [Effect of antidepressant and psychological intervention on the quality of life and blood pressure in hypertensive patients with depression]. Zhong Nan Da Xue Xue Bao Yi Xue Ban [Journal of Central South University (Med Sci)]. 2009;34(4):313–7. (In Chinese.) PMID: 19411747 9. Kanaeva LS. Remissii pri nepsihoticheskih depressivnyh rasstrojstvah (kompleksnyj analiz) [PhD thesis]. [Moscow (Russia)]: Gosudarstvennyj nauchnyj centr social'noj i sudebnoj psihiatrii im. V.P. Serbskogo [V.P. Serbsky State Scientific Center for Social and Forensic Psychiatry]; 2013. 37 p. (In Russ.) 10. YUdina NV. Psihicheskie rasstrojstva na nachal'nyh stadiyah essencial'noj arterial'noj gipertenzii [PhD thesis]. [Tomsk (Russia)]: Nauchno-issledovatel'skij institut psihicheskogo zdorov'ja Tomskogo nauchnogo centra SO RAMN [Research Institute of Mental Health of the Tomsk Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences]; 2009. 29 p. (In Russ.) 11. Jyotishman P, Simon G, Li D, et al. Detecting Associations between Major Depressive Disorder Treatment and Essential Hypertension using Electronic Health Records. AMIA Jt Summits Transl Sci Proc. 2014;7:91–6. PMID: 25954583 12. Mahadova KH, Halikova NA, Hamidov NH, Hursanov NM. [The use of rexetine in the treatment of elderly hypertensive patients with comorbid depression]. Vestnik Avicenny [Bulletin of Avicenna]. 2012;(4):102–5. (In Russ.) 13. Diminic-Lisica I, Popovic B, Rebic J, et al. Outcome of Treatment with Antidepressants in Patients with Hypertension and Undetected Depression. Int J Psychiatry Med. 2014;47(2):115–29. DOI: https://doi.org/10.2190/PM.47.2.c 14. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003;160(12):2122–7. DOI: https://doi.org/10.1176/appi.ajp.160.12.212 15. Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:102–11. DOI: https://doi.org/10.1016/j.pnpbp.2013.09.017
Article Metrics
Metrics powered by PLOS ALM